The benefit could also apply to amyotrophic lateral sclerosis (ALS). While the mechanism by which the gene therapy triggers these beneficial effects remains to be elucidated, this unexpected finding suggests that even gene therapy for rare specific gene defects may in some cases have broader applicability.
Recent developments have broadened the scope of gene therapy beyond the small group of simple diseases caused by a single gene defect. As outlined above, the possibility to introduce apoptosis genes into specific cells has opened up applications in cancer therapy. The company that got the first regulatory approval for gene therapy, uniQure, also has advanced development programmes targeting diseases like intermittent porphyria, Sanfilippo B, hemophilia B and Parkinson's disease.
Surprisingly, even patients with infectious diseases can benefit from gene therapy. Efforts are underway to use a rare gene variant that makes some people immune to HIV in the treatment of patients who have contracted the virus. An initial experimental treatment of a patient with leukaemia and HIV who received a bone marrow transplant from a donor with the resistance gene variant suggested that the idea works in principle, but that a less invasive implementation needs to be found.
In March this year, researchers reported first results of a phase I clinical study based on ex vivo gene editing to introduce the HIV-resistant trait into a population of lymphocytes which were then re-injected to the patients. While the trial was designed only to establish the safety, not the efficacy of the treatment, observations were encouraging, as several patients were able to keep the virus in check without their usual daily drugs (N. Engl. J. Med. (2014) 370, 901-910) .
The broad range of success stories emerging in the last few years has given researchers in the field fresh optimism, mirrored also in the activity of biotech entrepreneurs and venture capital firms. In spite of its troubled beginnings, it looks like gene therapy is now set to take up a significant role in clinical practice, fulfilling treatment needs that have proven elusive to conventional therapies.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk could not be among the best? The 'pull' was my enjoyment of human anatomy, combined with the realization that because of my good fortune to be involved with Richard Leakey's research team, I had the unique opportunity to help interpret the new evidence they were unearthing.
Why did you choose to work on skulls and teeth? I didn't. I was one of three anatomists (the others were Michael Day and Alan Walker) Richard Leakey had invited to describe and interpret the hominin fossils recovered from Lake Rudolf. The majority of the fossils were from the skull and dentition, but each of us wanted to work on the limb bones. In 1972, we met in New York to discuss the impasse, but none of us would give in. So, not a little frustrated, Richard broke three matches into different lengths and made us draw. Mine was the shortest match, so I had no choice but to work on the cranial remains. This task, which involved determining how many taxa were represented among the hominin cranial fossils, led to the topic of my PhD, sexual dimorphism, and my interest in patterns of intra-versus interspecific variation.
What do you enjoy most about being a paleoanthropologist? I have a passionate dislike of games of chance, but I do like solving real-life puzzles. All paleontology is challenging, but because we are trying to reconstruct human evolutionary history on Why did you initially choose medicine as a career? I was hopeless at languages -I had a debilitating stammer -and in those days you learned languages by reading out loud from a book and that was beyond me. But I was reasonably good at science and geography. My method for finding a possible career was unconventional but practical. My parents owned a grocery store. One of my chores was to deliver groceries on a bicycle. In general, when I delivered groceries to the houses of lawyers and accountants, I felt my efforts were unappreciated. There was, however, a medical household where I would always be given a glass of lemonade, and where my nascent interest in medicine was encouraged -Bill Clark even gave me his copy of a book of essays by Sir William Osler. It is still on my bookshelf. His kindness and solicitude are why I decided to become a doctor.
Bernard Wood
Why did you switch to paleoanthropology? There were elements of 'push' and 'pull': the 'push' was that I had the good fortune to be apprenticed to a surgeon whose diagnostic and clinical skills were legendary. However, he was so good that it was pretty clear to me that, no matter hard I worked at it, I was unlikely to be as good a such a fine scale, it is especially challenging. I get bored too easily, and paleoanthropology provides a seemingly unlimited opportunity to explore the potential of exciting topics, such as evo-devo, to help reduce our ignorance about human evolutionary history.
What features do you most admire in your colleagues? Intellectual horsepower coupled with generosity, humility and a sense of humor.
What features do you least admire in your colleagues? Self-righteousness, an unjustified sense of self-importance, a lack of generosity and the inability to laugh at yourself. In my experience, these traits are highly correlated.
Do you have a scientific hero?
That's a difficult one. The colleague I admire most for lots of reasons is the late Glynn Isaac, who was an archaeologist, not a paleoanthropologist. Glynn recognized that in the absence of the right careful and thoughtful research questions, even if you were drowning in data, you would be none the wiser. In most species, transcription of genes encoding most of the strigolactone biosynthesis enzymes is feedback regulated and regulated by the plant hormone auxin. Depending on the species, strigolactone levels are also influenced by nutrients, particularly phosphate.
Where are they produced? Strigolactones are not just made in roots. The biosynthetic genes are expressed strongly also in stems and grafting experiments indicate that shoot production of strigolactones might be most effective at inhibiting branching. About half of the biosynthetic pathway occurs in the plastid and subsequent steps produce molecules that can move over long distances, although apparently only in the direction of root to shoot.
What do they do? Like other plant hormones, strigolactones are involved in a complex wholeplant signalling network involving regulation of and by other plant hormones, light and nutrients. Some researchers believe that strigolactones may have evolved as a hormone for mediating wholeplant responses to nutrient status and environmental stress. For many species grown under low phosphate conditions, strigolactone exudation from roots is very high and encourages the symbiosis with AM fungi. At the same time,
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What are strigolactones?
Strigolactones are a family of small organic compounds with a four-ring structure as simple as 'ABCD'. The ABC rings carry one lactone and the D ring another lactone (often called the butenolide, just to confuse the non-chemists; Figure 1A ). There are many types of strigolactones and different species may have different representatives.
Where did the name come from?
Well the lactone part obviously came from the structure and the 'striga' part came from their first identified function. They were originally identified as very annoying molecules exuded from plant roots because they stimulated germination of very harmful parasitic weeds, such as Striga sp. and Orobanche sp. The term 'striga' comes from the Latin words strix or strigis, which mean witch or evil spirit. How were they discovered? As you may have already guessed, strigolactones were discovered as being the molecule perceived by parasitic weeds such as Striga to recognise the close proximity to a compatible root. Strigolactones exuded into the rhizosphere were later found to enhance the symbiotic relationship with arbuscular mycorrhizae (AM fungi), common in around 80% of land plants and which improves nutrient and water uptake by plants.
While these discoveries were occurring in the underworld, the above ground had its own mystery; a longdistance hormone controlling shoot branching was evading discovery. In a perfect example of 'a day in the library is worth months in the lab', these stories collided with the discovery that the shoot-branching hormone was derived from the same precursor as strigolactones and that this hormone was indeed strigolactone, or strigolactone-derived.
How are they made and regulated?
Strigolactones are derived from ß-carotene which, based on Quick guide
